FDA Approves J&J's Rybrevant Combo for NSCLC with EGFR Exon 20 Insertions

Johnson and Johnson announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients w

Global Healthcare Brands Eye India Opportunities - Chairman, Aaron Capital, Inc. USA

The current impediments to bilateral relations include tariff and non-tariff barriers, complex custom clearance procedures, IPR and data localization issues” - David Sanford Wolfe, Chairman, Aaron Capital, Inc USA.

Indian API Industry: Make in India & PLI to Limit China Imports

The Indian active pharmaceutical ingredient (API) industry believes that the Make in India initiative and the PLI (production-linked incentive) scheme will help limit imports from China.

CAHOCON 2024: Kolkata Global Healthcare Conclave - April 6 & 7

To revolutionize the healthcare landscape, the 8th Edition of CAHOCON 2024 is set to unfold between April 6 and 7 at the Biswa Bangla Convention Centre in Kolkata with a theme that resonates globally.

India To Become Major Exporter of Bulk Drugs: Health Minister

India has continued on toward turned into a significant exporter of bulk drugs and medical devices, Health Minister, Mansukh Mandaviya said. As per him, India dealt with plans and plans to de-risk its store network from worldwide ideas and...

Ginkgo Bioworks Buys Reverie Labs To Advance AI-driven Drug discovery

Ginkgo Bioworks, a startup developing the leading platform for cell programming and biosecurity, has announced the purchase of key assets from Reverie Labs, which created and applied AI/ML techniques to expedite drug discovery. Ginkgo has...

© 2024 India Pharma Outlook. All Rights Reserved.